LEGN · Legend Biotech Corp

Track LEGN — free

$19.89 +1.07 (+5.69%) At close · Sep 30

Rebalance outlook locked

Market Cap

$3.72B

194.49M

Volume · Sep 30 2.96M Avg daily vol (3M) 2.32M

Up next

Next earnings call

Nov 11, 2026 Est · unconfirmed · in 6 wks

Q1 2026 earnings call transcript

call held May 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

-42.7%

Trailing year

Short interest

7.5%

Latest settlement · 7.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High

Market backdrop VIX 16.3 · calm Equity put/call 0.53

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −11%

below

Price vs 50-day avg −1%

below

RSI (14) 53

neutral

MACD trend Positive

52-week position 17%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −6%

trailing

6-month return +9%

trailing

YTD return −9%

this year

Relative strength −3%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $20 › 200d $22 — 200d above 50d

Institutional flow Accumulating

+15% holders QoQ · +56 funds added

Insider flow Distributing

Net -$49.6K over 90 days · 100% sells

Short interest Falling

7.53% of float · ▼ -11.2% MoM · 7.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

221 holders — near 3-yr high, broad support

Squeeze score 61

elevated · 0–100

Fundamentals

Limited

Not enough data for a confident read.

Quant / Vol

risk profile

Very High

Volatility 74%

annualized · 1-yr

Max drawdown −53%

past year

ATR 4.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Mar 31, 2026

Gross margin · Q2 at least 50%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 5 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−11% Bearish

Price vs 50-day avg

−1% Neutral

RSI (14)

53 Neutral

MACD trend

Positive Bullish

52-week position

17% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $20 › 200d $22 — 200d above 50d

Institutional flow Accumulating

+15% holders QoQ · +56 funds added

Insider flow Distributing

Net -$49.6K over 90 days · 100% sells

Short interest Falling

7.53% of float · ▼ -11.2% MoM · 7.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

221 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $17 Now $20 · 17% Range high $36

vs 200-day avg -11% vs 50-day avg -1%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
LEGN Legend Biotech Corp this stock	$3.72B	-8.5%	—	—	7.5%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+15.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-1.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+553.0%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

221

% held: 53.5%
Net QoQ: +6.9M sh
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

160

View

Short & Settlement

Short Interest Falling

Shares short

14.6M

Days to cover: 7.1d
Change: -1.8M sh

View

Short Volume

Short vol %

54%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $358
As of: Aug 31, 2026

View

Off-Exchange

Off-exchange %

48.4%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$49.6K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Filings

SEC Filings

Latest

6-K

Filed: Sep 25, 2026
This year: 23

View

Proposed Sales

Value

$258.9K

Shares: 13.7K
Filed: Sep 29, 2026

View

Exempt Offerings

Offering

$200.0M

Filed: Apr 28, 2023

View

Earnings & Events

Earnings Calls

Last call

Sep 24, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
LEGN	+7.8%	-5.9%	+9.3%	-4.3%	-8.5%
SPY	-0.7%	+0.1%	+12.2%	-0.6%	+11.8%
vs SPY	+8.5%	-6.0%	-2.9%	-3.7%	-20.4%

Key facts CIK 1801198 CUSIP 52490G102 13F (30d) 6 filings 6 filers Visit website Investor relations

LEGN · Legend Biotech Corp

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance